Compare Citius Pharmaceuticals Inc (CTXR) vs ProShares UltraPro QQQ ETF (TQQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs ProShares UltraPro QQQ ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.53 (market cap $14.64M), while ProShares UltraPro QQQ ETF trades at $75.8. The key difference: ProShares UltraPro QQQ ETF is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | TQQQ | |
|---|---|---|
Market Cap | $14.64M | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $1.82 | $87.22 |
52-Week Low | $0.53 | $37.89 |
Enterprise Value | $10.86M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
TQQQ, a 3x leveraged ETF tracking the Nasdaq-100, trades at $72.64, down 5.7% in the last 24 hours amid a bearish technical signal. The fund lacks traditional financial ratios as it is not a company, and recent news highlights concerns over volatility amplification and hidden costs. Support is seen at $72, with resistance at $74.
Outlook is cautious due to leveraged structure magnifying losses in downturns; opportunities exist for tactical traders during tech rallies, but risks include daily rebalancing decay and market volatility. Long-term holders face significant drawdown risks, as seen in 2022's 81% drop versus Nasdaq's 33% decline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About ProShares UltraPro QQQ ETF
TQQQ is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the Nasdaq-100 Index. It is one of the most liquid and actively traded instruments in the market, designed for sophisticated traders to amplify short-term bullish exposure to large-cap non-financial growth stocks, predominantly in the technology and communication sectors.
Read more on TQQQ →
